Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eftozanermin alfa + Bortezomib + Dexamethasone in R/R MM
NCT04570631Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Nov 2020
- Primary completion
- May 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 1, open-label trial of eftozanermin in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Recommended Phase 2 Dose at 3 weeks and Objective Response Rate at 44 weeks. Started Nov 2020; status: terminated.
02
Drugs
eftozanermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04570631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570631.